Deuruxolitinib for adolescents with severe alopecia areata

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Adolescents 12 to <18 years with at least 50% scalp hair loss (SALT ≥50) are randomized in a double-blind, placebo-controlled 24-week treatment period to receive deuruxolitinib or placebo. After the randomized period, participants may enter a 52-week open-label extension in which all receive deuruxolitinib. Key exclusions include active scalp inflammatory conditions that interfere with assessment, recent use of other hair-regrowth or immunomodulatory therapies, and significant medical or psychiatric comorbidities. The study tracks hair regrowth measures and safety outcomes during treatment and long-term exposure.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Clinical presentation compatible with alopecia areata with a current episode lasting at least 6 months and not exceeding 10 years.
* Between 12 to \<18 years of age
* At least 50% scalp hair loss, as defined by a Severity of Alopecia Tool (SALT) score ≥50.
* Willing to comply with the study visits and requirements of the study protocol

Exclusion Criteria:

* Active scalp inflammation, psoriasis, or seborrheic dermatitis requiring topical treatment to the scalp, significant trauma to the scalp, or other scalp condition that may interfere with the SALT assessment, or untreated actinic keratosis at Screening and/or Baseline
* Treatment with other medications or agents within 28 days of Baseline or during the study that may affect hair regrowth or immune response.
* Females who are nursing, pregnant, or planning to become pregnant while in the study, and for 30 days after last dose of study drug.
* Clinically significant medical condition, psychiatric disease, or social condition, as determined by the Investigator, that may unfavorably alter the risk-benefit of study participation, adversely affect study compliance, or confound interpretation of study results.

Where it's running

• Total Skin And Beauty Dermatology Center
  Birmingham, Alabama, United States Recruiting
• Avacare - Cct Research - Center For Dermatology And Plastic Surgery
  Scottsdale, Arizona, United States Recruiting
• Dermatology Trial Associates
  Bryant, Arkansas, United States Recruiting
• Kern Research Inc.
  Bakersfield, California, United States Recruiting
• Center For Dermatology Clinical Research Inc.
  Fremont, California, United States Recruiting
• Dermatology Research Associates
  Los Angeles, California, United States Recruiting

+14 more sites. See ClinicalTrials.gov for the full list.

Study contacts

• Study coordinator: Head Regulatory Affairs
• Email: Clinical.Trial@sunpharma.com
• Phone: 9122 66455645

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Deuruxolitinib in Japanese Adults With Severe Alopecia Areata

  This study tests whether deuruxolitinib can help Japanese adults with 50% or more scalp hair loss compare to placebo.

  Recruiting at 17 sites Phase 3 Sun Pharma Japan Limited · Asahikawa and 17 other locations · NCT07617597

• Which works better for patchy hair loss: steroid injections or microneedling with steroid cream?

  This trial tests whether injecting triamcinolone into the skin or using microneedling with topical triamcinolone helps people with alopecia areata regrow hair more effectively.

  Recruiting Phase 4 Dow University of Health Sciences · Karachi, Sindh · NCT07926711

• Red Ultraviolet Hair Imaging and Hair Growth in Alopecia Areata

  This observational study checks if red fluorescence seen with UV hair imaging relates to disease features and how well hair regrows after standard intralesional corticosteroid treatment in adults with limited plaque-type alopecia areata.

  Recruiting Istanbul Training and Research Hospital · Istanbul · NCT07803874

• VC005 tablets in teens with severe alopecia areata

  This Phase 1 study tests VC005 tablets in adolescents with severe alopecia areata to see how the drug behaves in the body, whether it is safe, and if there are signs of benefit.

  Recruiting Phase 1 Jiangsu vcare pharmaceutical technology co., LTD · Beijing, Beijing Municipality · NCT07762443

• VC005 tablets in severe alopecia areata

  This study tests whether VC005 tablets work better than a placebo for adults with severe alopecia areata.

  Recruiting Phase 2 Jiangsu vcare pharmaceutical technology co., LTD · Beijing, Beijing Municipality · NCT07749716

• Ritlecitinib for patchy hair loss in teens and adults with alopecia areata

  This study tests whether ritlecitinib can help people 12 and older with patchy alopecia areata who have had symptoms for 6 months to 10 years.

  Recruiting at 30 sites Phase 3 Pfizer · Encinitas, California and 37 other locations · NCT07733765

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.